Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abuse Potential of Lemborexant in Recreational Sedative Users
NCT03158025Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Apr 2017
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lemborexant in Insomnia (6 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Mean peak Maximum Effect (Emax) score for Drug Liking on a Visual Analog Scale (VAS). Started Apr 2017; status: completed.
02
Drugs
lemborexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT03158025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03158025.